Real-world outcomes of FOLFOXIRI plus bevacizumab in patients with metastatic colorectal cancer: the JSCCR-TRIPON study-Reference-Cited by-同舟云学术

Real-world outcomes of FOLFOXIRI plus bevacizumab in patients with metastatic colorectal cancer: the JSCCR-TRIPON study

Published:2024-08-28 Issue: Volume: Page:
ISSN:1341-9625
Container-title:International Journal of Clinical Oncology
language:en
Short-container-title:Int J Clin Oncol

Author:

Yamamoto Yoshiyuki,Yukami Hiroki,Yamaguchi Tatsuro,Ohori Hisatsugu,Nagasu Sachiko,Kagawa Yoshinori,Sugimoto Naotoshi,Sonoda Hiromichi,Yamazaki Kentaro,Takashima Atsuo,Okuyama Hiroyuki,Hasegawa Hiroko,Kondo Chihiro,Baba Eishi,Matsumoto Toshihiko,Kawamoto Yasuyuki,Kataoka Masato,Shindo Yoshiaki,Ishikawa Toshiaki,Esaki Taito,Kito Yosuke,Sato Takeo,Funakoshi Taro,Yamaguchi Toshifumi,Shimada Yasuhiro,Moriwaki Toshikazu^ORCID

Funder

the Japanese Society for Cancer of the Colon and Rectum

Publisher

Springer Science and Business Media LLC

Link

https://link.springer.com/content/pdf/10.1007/s10147-024-02613-0.pdf

Reference19 articles.

1. Cremolini C, Loupakis F, Antoniotti C et al (2015) FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study. Lancet Oncol 16:1306–1315

2. Loupakis F, Cremolini C, Masi G et al (2014) Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer. N Engl J Med 371:1609–1618

3. Watanabe J, Muro K, Shitara K et al (2023) Panitumumab vs bevacizumab added to standard first-line chemotherapy and overall survival among patients with RAS wild-type, left-sided metastatic colorectal cancer: a randomized clinical trial. JAMA 329:1271–1282

4. Yamazaki K, Nagase M, Tamagawa H et al (2016) Randomized phase III study of bevacizumab plus FOLFIRI and bevacizumab plus mFOLFOX6 as first-line treatment for patients with metastatic colorectal cancer (WJOG4407G). Ann Oncol 27:1539–1546

5. Falcone A, Ricci S, Brunetti I et al (2007) Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nord Ovest. J Clin Oncol 25:1670–1676